Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Phase 2
Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 5
- Registration Number
- NCT05176925
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Phase 2
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 136
- Registration Number
- NCT05174832
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Phase 2
Recruiting
- Conditions
- Atypical Endometrial HyperplasiaFertility IssuesObesity
- Interventions
- Device: levonorgestrel-releasing intrauterine systemDrug: Polyethylene Glycol Loxenatide
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 28
- Registration Number
- NCT05172999
- Locations
- 🇨🇳
Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Phase 2
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Fruquintinib,Albumin Paclitaxel,Gemcitabine
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05168527
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Value of ctDNA in the Treatment of Multiple Primary Cancers
Phase 2
- Conditions
- Multiple Primary Cancers
- Interventions
- Genetic: ct-DNA guided therapy
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT05164510
- Locations
- 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Stomach NeoplasmsEsophagogastric Junction DisorderNeoadjuvant TherapyChemoradiotherapyImmunotherapyGastrectomyAdenocarcinomaAdjuvant Therapy
- Interventions
- Drug: OxaliplatinDrug: Tegafur-Gimeracil-OteracilDrug: SintilimabRadiation: Concurrent chemoradiationProcedure: D2/R0 gastrectomy
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 152
- Registration Number
- NCT05161572
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
Not Applicable
Recruiting
- Conditions
- Circulating Tumor DNAStage III Colorectal Cancer
- Interventions
- Diagnostic Test: ctDNA dynamic monitoring
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 316
- Registration Number
- NCT05161585
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy
Recruiting
- Conditions
- KCNQ2-related Epilepsy
- Interventions
- Other: Electrophysiological detection of KCNQ2 mutationOther: Multi-modal brain image and EEGOther: Omics testing
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05157737
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Titration of Intraoperative PEEP in Patients Undergoing Robotic Assisted Laparoscopic Prostatectomy
Not Applicable
Completed
- Conditions
- Positive End Expiratory Pressure
- Interventions
- Other: Titration of Optimal Positive End-expiratory Pressure
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 95
- Registration Number
- NCT05155371
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Active, not recruiting
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Anti-PD-1 Immune Checkpoint Inhibitors
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT05142709
- Locations
- 🇨🇳
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The 1st affiliated hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath